[Cytostatic therapy: neurologic and psychiatric syndromes].
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001215:Asparaginase / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D003606:Dacarbazine / Q000009:adverse effects; D003609:Dactinomycin / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects; D009422:Nervous System Diseases / Q000139:chemically induced*; D009607:Nitrosourea Compounds / Q000009:adverse effects; D011344:Procarbazine / Q000009:adverse effects; D011605:Psychoses, Substance-Induced / Q000209:etiology*; D014750:Vincristine / Q000009:adverse effects
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D003561:Cytarabine; D003609:Dactinomycin; D011344:Procarbazine; D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase; D005472:Fluorouracil; D008727:Methotrexate
Zytostatische Therapie Neurologische und psychiatrische Syndrome.